Connect with us

Research Reports

Radiation Toxicity Treatment Market will reach the value of US$ 5.5 Billion by the end of forecast period 2019 – 2029

Radiation Toxicity Treatment Market will reach the value of US$ 5.5 Billion by the end of forecast period 2019 - 2029 1

 

The rise in installation of radiation therapy machines to treat a wide range of cancers further uplifts the probability of radiation toxicity in cancer patients. Future Market Insights (FMI), in its new study on the global radiation toxicity treatment market, foresees that the market will reach the value of US$ 5.5 Bn by the end of forecast period (2019 – 2029) and further experience a major upturn post 2029.

Installed base of internal radiation therapy machines has tremendously increased over the past decade. Improving reimbursement scenario and favorable government policy framework in the field of cancer care are adding to the accessibility of radiation therapy, thereby favoring the growth of radiation toxicity treatment market. The study suggests that notable players in Asia Pacific will continue to invest heavily in the development of new radiation therapies, in line with the increasing cancer prevalence and improving rate of diagnosis in the region.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-10724

Key Takeaways – Radiation Toxicity Treatment Market Study

  • Increasing adoption of colony stimulating factors such as Neulasta from Amgen will account for more than 75% of revenue share in the radiation toxicity treatment market through 2029 end.
  • Attributed to high incidences of radiation toxicity due to emission of gamma radiation from positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners installed at hospitals and diagnostic centers, non-ionizing radiation is also set to offer lucrative opportunity to market participants.
  • North America continues to lead its way in the radiation toxicity treatment market, while South Asia is foreseen to grow at a significant rate in the near future.

Who Is Winning?

Some of the key players operating in the radiation toxicity treatment market include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players of the radiation toxicity treatment market are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning. For instance, Siegfried Group announced the acquisition of drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

Get a Customized Scope to Match Your Need, Ask an Experthttps://www.futuremarketinsights.com/ask-question/rep-gb-10724

Know More About the Report

Radiation toxicity treatment market, a new study from future market insights, opines on the evolution of the radiation toxicity treatment market from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of; product type (colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and others), indication (acute radiation syndrome and chronic radiation syndrome), radiation type (ionizing radiation and non-ionizing radiation) and end user (hospitals and research & academic institutes) across seven prominent regions.

Explore Wide-ranging Coverage of FMI’s Market Insights Landscape:

  1. Radiation Therapy Software Market
  2. Radiation-Induced Myelosuppression Treatment Market
  3. Radiation Protection Cabins Market

 

Editorial & Advertiser disclosure
Our website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Recommended

Newsletters with Secrets & Analysis. Subscribe Now